A Phase 1 interventional study of MSC1936369B and MSC1936369B in Solid Tumors and Cancer, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 9 sites in 4 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-23.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This is a first in man trial with a primary objective being the determination of the Maximum Tolerated dose (MTD) and the dose-limiting toxicity (DLT) in several regimens of MEK inhibitor MSC1936369B administered orally once a day, in subjects with malignant solid tumors to see how safe is treatment with MSC1936369B.
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 182 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will be administered MSC1936369B (pimasertib) capsules 1 to 120 milligram (mg) orally, once daily (QD) on Days 1 to 5, 8 to 12, 15 to 19 of each 21-day treatment cycle until progressive disease (PD) or intolerable toxicity or investigator/subject decision.
Drug: MSC1936369B
MSC1936369B Regimen 2 (Without Food Effect): Subjects will be administered MSC1936369B capsules 1 to 255 mg orally QD on Days 1 to 15 of each 21-day treatment cycle until PD or intolerable toxicity or investigator/subject decision. MSC1936369B Regimen 2 (With Food Effect): : Subjects will be administered MSC1936369B capsules 90 or 150 mg orally QD on Day 1 to 15 of each 21-day treatment cycle until PD or intolerable toxicity or investigator/subject decision. Subjects in the Regimen 2 FE cohort were assigned in a 1:1 ratio to either the fed/fasted sequence or fasted/fed sequence for Day 1 of Cycle 1 and Day 1 of Cycle 2.
Drug: MSC1936369B
Subjects will be administered MSC1936369B capsules 60 to 90 mg orally QD in each 21-day treatment cycle until PD or intolerable toxicity or investigator/subject decision.
Drug: MSC1936369B
Subjects will be administered MSC1936369B capsules 45 to 75 mg orally BID in each 21-day treatment cycle until PD or intolerable toxicity or investigator/subject decision.
Drug: MSC1936369B
Also known as: Pimasertib
Also known as: Pimasertib
Also known as: Pimasertib
Also known as: Pimasertib
Number of Subjects Experienced Any Dose-Limiting Toxicity (DLT) Over the First Cycle - Day 1 to 21
DLT was defined as any of following toxicities at any dose level according to using National Cancer Institute Common Terminology Criteria for Adverse Events (AEs) v3.0(CTCAE), probably or possibly related to trial medication by investigator or sponsor: a)Any Grade 3 or more non-haematological toxicity excluding: (i)Grade 3 asymptomatic increase in liver function tests (Aspartate Aminotransferase, Alanine transaminase, Alkaline Phosphatase reversible within 7 days for subjects without liver involvement, or grade 4 for subjects with liver involvement; (ii)Grade 3 vomiting if it is encountered despite adequate and optimal therapy (e.g. serotonin \[5HT3\] antagonists and corticosteroids); (iii)Grade 3 diarrhoea if it is encountered despite adequate and optimal anti diarrhoea therapy; b)Grade 4 neutropenia of \>5 days duration or febrile neutropenia lasting for more than 1 day; c)Grade 4 thrombocytopenia \>1 day or grade 3 with bleeding; d)Any treatment delay \>2 weeks due to drug-related AEs.
Time frame: Day 1 up to Day 21 of Cycle 1
Number of Subjects With Treatment-Emergent Adverse Events (TEAE), Serious TEAEs, TEAEs Leading to Discontinuation
AE was defined as any untoward medical occurrence which does not necessarily have a causal relationship with this the study drug. An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent are events between first dose of study drug and up to 253 weeks. TEAEs include both Serious TEAEs and non-serious TEAEs.
Time frame: Baseline up to 253 weeks
Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) Leading to Death
Time frame: Baseline up to 253 weeks
Number of Subjects With Clinical Significant Laboratory Abnormalities and Vital Signs Reported as Treatment Emergent Adverse Events
Any clinically significant changes in laboratory evaluations and vital signs were recorded as treatment emergent adverse events. The clinical laboratory parameters that were assessed included: Hematological parameters, Blood chemistry parameters, Urinalysis and the vital signs that were assessed included: Blood pressure, Heart rate, Temperature and Weight. SAF analysis was used.
Time frame: Baseline up to 253 weeks
Maximum Observed Plasma Concentration (Cmax) of MSC1936369B: Regimen 1
Pharmacokinetic (PK) parameter Cmax was obtained directly from the concentration versus time curve.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours (h) post-dose on Cycle 1(C1) Day 1 (D1), Cycle 1 Day 12 (D12) and Cycle 3 (C3) Day 1
Maximum Observed Plasma Concentration (Cmax) of MSC1936369B: Regimen 2 (Without Food Effect)
Cmax was obtained directly from the concentration versus time curve.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1
Maximum Observed Plasma Concentration (Cmax) of MSC1936369B: Regimen 2 (With Food Effect)
Cmax was obtained directly from the concentration versus time curve. Summarized data over Day 1 and Day 2 was reported.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12 and 24 hours post-dose on Cycle 1 Day 1 and Day 2
Maximum Observed Plasma Concentration (Cmax) of MSC1936369B: Regimen 3 Once Daily
Cmax was obtained directly from the concentration versus time curve.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1
Maximum Observed Plasma Concentration (Cmax) of MSC1936369B: Regimen 3 Twice Daily
Cmax was obtained directly from the concentration versus time curve.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, and 10 h post-dose on Cycle 1 Day 1 and Day 15; pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 h post dose on Cycle 3 Day 1
Time to Reach Maximum Plasma Concentration (Tmax) of MSC1936369B: Regimen 1
Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 12 and Cycle 3 Day 1
Time to Reach Maximum Plasma Concentration (Tmax) of MSC1936369B: Regimen 2 (Without Food Effect)
Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1
Time to Reach Maximum Plasma Concentration (Tmax) of MSC1936369B: Regimen 2 (With Food Effect)
Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve. Summarized data over Day 1 and Day 2 was reported.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12 and 24 hours post-dose on Cycle 1 Day 1 and Day 2
Time to Reach Maximum Plasma Concentration (Tmax) of MSC1936369B: Regimen 3 Once Daily
Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1
Time to Reach Maximum Plasma Concentration (Tmax) of MSC1936369B: Regimen 3 Twice Daily
Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, and 10 h post-dose on Cycle 1 Day 1 and Day 15; pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 h post dose on Cycle 3 Day 1
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of MSC1936369B: Regimen 1
Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 12 and Cycle 3 Day 1
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of MSC1936369B: : Regimen 2 (Without Food Effect)
Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of MSC1936369B: Regimen 2 (With Food Effect)
Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule. Summarized data over Day 1 and Day 2 was reported.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12 and 24 hours post-dose on Cycle 1 Day 1 and Day 2
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of MSC1936369B: Regimen 3 Once Daily
Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1
Area Under the Plasma Concentration-time Curve From Time Zero to the Last Sampling Time at Which the Concentration is at or Above the Lower Limit of Quantification (AUC0-t) of MSC1936369B: Regimen 3 Twice Daily
Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, and 10 h post-dose on Cycle 1 Day 1 and Day 15; pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 h post dose on Cycle 3 Day 1
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MSC1936369B : Regimen 1
AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 12 and Cycle 3 Day 1
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MSC1936369B: Regimen 2 (Without Food Effect)
AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration was at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MSC1936369B: Regimen 2 (With Food Effect)
AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase. Summarized data over Day 1 and Day 2 was reported.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12 and 24 hours post-dose on Cycle 1 Day 1 and Day 2
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MSC1936369B: Regimen 3 Twice Daily
AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, and 10 h post-dose on Cycle 1 Day 1 and Day 15; pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 h post dose on Cycle 3 Day 1
Area Under the Plasma Concentration-time Curve From Time Zero to Infinity (AUC0-inf) of MSC1936369B: Regimen 3 Once Daily
AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1
Apparent Terminal Half-life (t1/2) of MSC1936369B: Regimen 1
Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz. As AUCextra was \>20% of AUC0-inf, t1/2 derived from λz was regarded as implausible \& not calculated for arms MSC1936369B 1mg, 1.5mg, 2.5 mg.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 12 and Cycle 3 Day 1
Apparent Terminal Half-life (t1/2) of MSC1936369B: Regimen 2 (Without Food Effect)
Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz. As AUCextra was \>20% of AUC0-inf, t1/2 derived from λz was regarded as implausible \& not calculated for arms MSC1936369B 1mg, 2mg, 3.5 mg.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1
Apparent Terminal Half-life (t1/2) of MSC1936369B: Regimen 2 (With Food Effect)
Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz. Summarized data over Day 1 and Day 2 was reported.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12 and 24 hours post-dose on Cycle 1 Day 1 and Day 2
Apparent Terminal Half-life (t1/2) of MSC1936369B: Regimen 3 Once Daily
Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1
Apparent Terminal Half-life (t1/2) of MSC1936369B: Regimen 3 Twice Daily
Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, and 10 h post-dose on Cycle 1 Day 1 and Day 15; pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 h post dose on Cycle 3 Day 1
Total Body Clearance From Plasma Following Extravascular Administration (CL/f) of MSC1936369B: Regimen 1
Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from plasma, CL= Dose/AUC0-inf. As AUCextra was \>20% of AUC0-inf, CL/f derived from λz was regarded as implausible \& not calculated for arms MSC1936369B 1mg, 1.5mg, 2.5 mg.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 12 and Cycle 3 Day 1
Total Body Clearance From Plasma Following Extravascular Administration (CL/f) of MSC1936369B: Regimen 2 (Without Food Effect)
Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from plasma, CL= Dose/AUC0-inf. As AUCextra was \>20% of AUC0-inf, CL/f derived from λz was regarded as implausible \& not calculated for arms MSC1936369B 1mg, 2mg, 3.5 mg.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1
Total Body Clearance From Plasma Following Extravascular Administration (CL/f) of MSC1936369B: Regimen 2 (With Food Effect)
Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from plasma, CL= Dose/AUC0-inf. Summarized data over Day 1 and Day 2 was reported.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12 and 24 hours post-dose on Cycle 1 Day 1 and Day 2
Total Body Clearance From Plasma Following Extravascular Administration (CL/f) of MSC1936369B: Regimen 3 Once Daily
Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from plasma, CL= Dose/AUC0-inf.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1
Total Body Clearance From Plasma Following Extravascular Administration (CL/f) of MSC1936369B: Regimen 3 Twice Daily
Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from plasma, CL= Dose/AUC0-inf.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, and 10 h post-dose on Cycle 1 Day 1 and Day 15; pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 h post dose on Cycle 3 Day 1
Apparent Volume of Distribution Following Extravascular Administration (Vz/F) of MSC1936369B: Regimen 1
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz. As AUCextra was \>20% of AUC0-inf, Vz/F derived from λz was regarded as implausible \& not calculated for arms MSC1936369B 1mg, 1.5mg, 2.5 mg.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 12 and Cycle 3 Day 1
Apparent Volume of Distribution During the Terminal Phase Following Extravascular Administration (Vz/F) of MSC1936369B: Regimen 2 (Without Food Effect)
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz. As AUCextra was \>20% of AUC0-inf, Vz/F derived from λz was regarded as implausible \& not calculated for arms MSC1936369B 1mg, 2mg, 3.5 mg.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1
Apparent Volume of Distribution During the Terminal Phase Following Extravascular Administration (Vz/F) of MSC1936369B: Regimen 2 (With Food Effect)
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz. Summarized data over Day 1 and Day 2 was reported.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12 and 24 hours post-dose on Cycle 1 Day 1 and Day 2
Apparent Volume of Distribution During the Terminal Phase Following Extravascular Administration (Vz/F) of MSC1936369B: Regimen 3 Once Daily
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1
Apparent Volume of Distribution During the Terminal Phase Following Extravascular Administration (Vz/F) of MSC1936369B: Regimen 3 Twice Daily
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, and 10 h post-dose on Cycle 1 Day 1 and Day 15; pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 h post dose on Cycle 3 Day 1
Area Under the Concentration Time Curve Extrapolated From Last Observation to Infinity Given as Percentage of AUC 0-∞ (AUC Extra): Regimen 1
AUCextra was defined as a percentage of AUC0-inf obtained by extrapolation: %AUCextra = (1- \[AUC0-t / AUC0-inf\])\*100. %AUCextra was reported in terms of percentage of AUC0-inf.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 12 and Cycle 3 Day 1
Area Under the Concentration Time Curve Extrapolated From Last Observation to Infinity Given as Percentage of AUC 0-∞ (AUC Extra): Regimen 2 (Without Food Effect)
AUCextra was defined as a percentage of AUC0-inf obtained by extrapolation: %AUCextra = (1- \[AUC0-t / AUC0-inf\])\*100. %AUCextra was reported in terms of percentage of AUC0-inf.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1
Area Under the Concentration Time Curve Extrapolated From Last Observation to Infinity Given as Percentage of AUC 0-∞ (AUC Extra): Regimen 2 (With Food Effect)
AUCextra was defined as a percentage of AUC0-inf obtained by extrapolation: AUCextra = (1- \[AUC0-t / AUC0-inf\])\*100. AUCextra was reported in terms of percentage of AUC0-inf. Summarized data over Day 1 and Day 2 was reported.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, 12 and 24 hours post-dose on Cycle 1 Day 1 and Day 2
Area Under the Concentration Time Curve Extrapolated From Last Observation to Infinity Given as Percentage of AUC 0-∞ (AUC Extra): Regimen 3 Once Daily
AUCextra was defined as a percentage of AUC0-inf obtained by extrapolation: AUCextra = (1- \[AUC0-t / AUC0-inf\])\*100. AUCextra was reported in terms of percentage of AUC0-inf.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 and 24 hours post-dose on Cycle 1 Day 1, Cycle 1 Day 15 and Cycle 3 Day 1
Area Under the Concentration Time Curve Extrapolated From Last Observation to Infinity Given as Percentage of AUC 0-∞ (AUC Extra): Regimen 3 Twice Daily
AUCextra was defined as a percentage of AUC0-inf obtained by extrapolation: AUCextra = (1- \[AUC0-t / AUC0-inf\])\*100. AUCextra was reported in terms of percentage of AUC0-inf.
Time frame: Pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8, and 10 h post-dose on Cycle 1 Day 1 and Day 15; pre-dose, 0.5, 1, 1.5, 2, 2.5, 4, 6, 8 h post dose on Cycle 3 Day 1
Phosphorylated Extra-Cellular Signal-Regulated Kinase (pERK) Fold Change in Peripheral Blood Monocyte Cells (PBMC) and Tot ERK Fold Change in Peripheral Blood Monocyte Cells (PBMC)
Time frame: Pre-dose on C1D1, C1D2, C1D5, C1D8; 2, 4, 8 h post-dose on C1D1; pre-dose, 2, 8, 24 h post-dose on C1D12-15; pre-dose, 2, 4 h post-dose on C1D3
Number of Subjects With Clinical Benefit (Complete Response [CR], Partial Response [PR] or Stable Disease [SD}) and Progressive Disease (PD) Based on the Best Overall Response (BOR)
Number of subjects with clinical benefit (CR, PR, or SD) and PD according to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0) was reported. CR: defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: defined as at least a 30% decrease in sum of longest diameter of target lesions, taking as reference the baseline sum of longest diameter. PD:defined as at least a 20% increase in sum of longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) or unequivocal progression of existing non-target lesions. SD: defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of longest diameter while on study.
Time frame: Baseline until disease progression (assessed up to end of treatment [253 weeks])
First/last subject (informed consent): December 2007/March 2012. Last subject completed: April 2016.
| Milestone | MSC1936369B Regimen 1 | MSC1936369B Regimen 2 (Without Food Effect + With Food Effect) | MSC1936369B Regimen 3 Once Daily (QD) | MSC1936369B Regimen 3 Twice Daily (BID) |
|---|---|---|---|---|
| Started | 49 | 82 | 15 | 34 |
| Completed | 49 | 82 | 15 | 34 |
| Not completed | 0 | 0 | 0 | 0 |
DLT was defined as any of following toxicities at any dose level according to using National Cancer Institute Common Terminology Criteria for Adverse Events (AEs) v3.0(CTCAE), probably or possibly related to trial medication by investigator or sponsor: a)Any Grade 3 or more non-haematological toxicity excluding: (i)Grade 3 asymptomatic increase in liver function tests (Aspartate Aminotransferase, Alanine transaminase, Alkaline Phosphatase reversible within 7 days for subjects without liver involvement, or grade 4 for subjects with liver involvement; (ii)Grade 3 vomiting if it is encountered despite adequate and optimal therapy (e.g. serotonin \[5HT3\] antagonists and corticosteroids); (iii)Grade 3 diarrhoea if it is encountered despite adequate and optimal anti diarrhoea therapy; b)Grade 4 neutropenia of \>5 days duration or febrile neutropenia lasting for more than 1 day; c)Grade 4 thrombocytopenia \>1 day or grade 3 with bleeding; d)Any treatment delay \>2 weeks due to drug-related AEs.
| Subjects | MSC1936369B Regimen 1 | MSC1936369B Regimen 2 (Without Food Effect + With Food Effect) | MSC1936369B Regimen 3 Once Daily (QD) | MSC1936369B Regimen 3 Twice Daily |
|---|---|---|---|---|
| Number of Subjects Experienced Any Dose-Limiting Toxicity (DLT) Over the First Cycle - Day 1 to 21 | 2 | 6 | 0 | 6 |
AE was defined as any untoward medical occurrence which does not necessarily have a causal relationship with this the study drug. An AE was defined as any unfavourable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug. A serious AE was an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. Treatment-emergent are events between first dose of study drug and up to 253 weeks. TEAEs include both Serious TEAEs and non-serious TEAEs.
| Subjects | MSC1936369B Regimen 1 | MSC1936369B Regimen 2 (Without Food Effect + With Food Effect) | MSC1936369B Regimen 3 Once Daily (QD) | MSC1936369B Regimen 3 Twice Daily |
|---|---|---|---|---|
| TEAEs | 47 | 82 | 15 | 34 |
| Serious TEAEs | 23 | 45 | 8 | 21 |
| TEAEs leading to discontinuation | 13 | 22 | 2 | 6 |
| Subjects | MSC1936369B Regimen 1 | MSC1936369B Regimen 2 (Without Food Effect + With Food Effect) | MSC1936369B Regimen 3 Once Daily (QD) | MSC1936369B Regimen 3 Twice Daily |
|---|---|---|---|---|
| Number of Subjects With Treatment-Emergent Adverse Events (TEAEs) Leading to Death | 10 | 14 | 2 | 2 |
Any clinically significant changes in laboratory evaluations and vital signs were recorded as treatment emergent adverse events. The clinical laboratory parameters that were assessed included: Hematological parameters, Blood chemistry parameters, Urinalysis and the vital signs that were assessed included: Blood pressure, Heart rate, Temperature and Weight. SAF analysis was used.
| Subjects | MSC1936369B Regimen 1 | MSC1936369B Regimen 2 (Without Food Effect + With Food Effect) | MSC1936369B Regimen 3 Once Daily (QD) | MSC1936369B Regimen 3 Twice Daily |
|---|---|---|---|---|
| Haemoglobin decreased | 1 | 2 | 0 | 0 |
| Anaemia | 10 | 23 | 3 | 3 |
| Lymphopenia | 3 | 7 | 0 | 0 |
| Thrombocytopenia | 3 | 6 | 2 | 1 |
| Platelet count decreased | 0 | 1 | 0 | 0 |
| Neutropenia | 0 | 4 | 0 | 1 |
| Leukopenia | 0 | 0 | 1 | 0 |
| Pancytopenia | 0 | 0 | 0 | 1 |
| Hyponatraemia | 0 | 1 | 0 | 1 |
| Hypokalaemia | 4 | 10 | 2 | 2 |
| Hyperkalaemia | 1 | 0 | 0 | 0 |
| Hypocalcaemia | 2 | 7 | 0 | 1 |
| Hypercalcaemia | 0 | 3 | 0 | 0 |
| Hypomagnesaemia | 2 | 3 | 2 | 0 |
| Hypophosphataemia | 0 | 2 | 0 | 0 |
| Hepatic enzyme increased | 0 | 1 | 0 | 0 |
| Hepatic function abnormal | 0 | 1 | 0 | 0 |
| Alanine aminotransferase increased | 0 | 1 | 0 | 2 |
| Aspartate aminotransferase increased | 1 | 1 | 0 | 2 |
| Blood alkaline phosphatase increased | 1 | 0 | 0 | 1 |
| Hyperbilirubinaemia | 1 | 1 | 0 | 0 |
| Blood lactate dehydrogenase increased | 1 | 0 | 0 | 1 |
| Blood creatine phosphokinase increased | 1 | 2 | 1 | 5 |
| Blood creatinine increased | 0 | 1 | 0 | 0 |
| Blood 25-hydroxycholecalciferol decreased | 1 | 1 | 0 | 0 |
| Vitamin D decreased | 0 | 1 | 0 | 0 |
| Blood parathyroid hormone increased | 1 | 1 | 0 | 0 |
| Hyperglycaemia | 0 | 1 | 0 | 0 |
| C-reactive protein increased | 0 | 1 | 0 | 0 |
| Proteinuria | 0 | 0 | 1 | 1 |
| Hyperthyroidism | 0 | 0 | 0 | 1 |
| Hypoalbuminaemia | 3 | 4 | 0 | 2 |
| Weight increased | 0 | 3 | 0 | 3 |
| Weight decreased | 6 | 8 | 4 | 2 |
| Hyperthermia | 1 | 5 | 0 | 1 |
| Hypertension | 7 | 5 | 1 | 4 |
| Hypotension | 3 | 1 | 2 | 0 |
| Heart rate increased | 1 | 0 | 0 | 0 |
| Tachycardia | 3 | 0 | 2 | 0 |
| Blood potassium increased | 1 | 0 | 0 | 0 |
Pharmacokinetic (PK) parameter Cmax was obtained directly from the concentration versus time curve.
| nanogram per milliliter (ng/mL) | MSC1936369B 1 mg | MSC1936369B 1.5 mg | MSC1936369B 2.5 mg | MSC1936369B 3.5 mg | MSC1936369B 7 mg | MSC1936369B 14 mg | MSC1936369B 28 mg | MSC1936369B 45 mg | MSC1936369B 68 mg | MSC1936369B 94 mg | MSC1936369B 120 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| C1D1 | 2.02 ± 41.0 | 3.20 ± 45.5 | 4.21 ± 47.9 | 6.69 ± 62.9 | 12.60 ± 15.4 | 62.32 ± 33.6 | 126.21 ± 70.2 | 212.96 ± 106.3 | 357.39 ± 30.7 | 325.99 ± 31.8 | 428.85 ± 57.9 |
| C1D12 | 2.92 ± 39.0 | 2.69 ± 10.1 | 6.29 ± 40.6 | 9.75 ± 63.3 | 21.93 ± 110.5 | 54.47 ± 116.2 | 150.67 ± 78.1 | 175.94 ± 47.5 | 413.58 ± 9.1 | 602.12 ± 11.0 | 425.26 ± 71.0 |
| C3D1 | 2.00 ± NA | 2.90 ± NA | 5.60 ± NA | 8.06 ± 30.3 | 10.90 ± 68.5 | 51.30 ± NA | 84.70 ± 78.8 | 167.75 ± 15.5 | — | 282.44 ± 14.9 | 652.70 ± 48.3 |
Cmax was obtained directly from the concentration versus time curve.
| ng/mL | MSC1936369B 1 mg | MSC1936369B 2 mg | MSC1936369B 3.5 mg | MSC1936369B 5 mg | MSC1936369B 7 mg | MSC1936369B 14 mg | MSC1936369B 28 mg | MSC1936369B 45 mg | MSC1936369B 68 mg | MSC1936369B 94 mg | MSC1936369B 120 mg | MSC1936369B 150 mg | MSC1936369B 195 mg | MSC1936369B 255 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C1D1 | 1.65 ± 59.2 | 2.87 ± 56.6 | 4.55 ± 113.4 | 17.26 ± 27.8 | 30.90 ± 32.6 | 39.19 ± 69.7 | 187.98 ± 39.7 | 321.85 ± 32.7 | 306.63 ± 110.4 | 373.59 ± 24.9 | 605.11 ± 48.8 | 539.02 ± 78.0 | 680.87 ± 45.6 | 990.92 ± 64.9 |
| C1D15 | 2.28 ± 58.0 | 7.77 ± 96.2 | 4.21 ± 39.9 | 18.78 ± 32.2 | 18.47 ± 33.1 | 34.87 ± 36.8 | 131.71 ± 14.7 | 286.88 ± 21.8 | 539.17 ± 37.1 | 432.46 ± 7.6 | 492.81 ± 117.1 | 450.29 ± 67.4 | 629.85 ± 71.3 | 1535.60 ± 57.1 |
| C3D1 | 1.25 ± 5.7 | 4.30 ± NA | 6.56 ± 39.8 | 14.81 ± 50.1 | 16.10 ± NA | — | 96.60 ± NA | — | 710.94 ± 57.4 | 532.80 ± NA | 568.49 ± 76.2 | 795.86 ± 50.0 | 773.14 ± 51.0 | 2344.91 ± 23.1 |
Cmax was obtained directly from the concentration versus time curve. Summarized data over Day 1 and Day 2 was reported.
| ng/mL | MSC1936369B 90 mg | MSC1936369B 150 mg |
|---|---|---|
| Fasted | 321.14 ± 58.3 | 1158.00 ± NA |
| Fed | 305.94 ± 45.6 | 370.70 ± NA |
Cmax was obtained directly from the concentration versus time curve.
| ng/mL | MSC1936369B 60 mg | MSC1936369B 90 mg |
|---|---|---|
| C1D1 | 241.27 ± 47.0 | 402.77 ± 59.2 |
| C1D15 | 316.08 ± 34.9 | 324.80 ± 65.8 |
| C3D1 | 473.27 ± 38.7 | 376.62 ± 45.2 |
Cmax was obtained directly from the concentration versus time curve.
| ng/mL | MSC1936369B 45 mg | MSC1936369B 60 mg | MSC1936369B 75 mg |
|---|---|---|---|
| C1D1 | 132.57 ± 40.2 | 206.46 ± 41.7 | 263.08 ± 68.5 |
| C1D15 | 178.09 ± 95.0 | 231.12 ± 44.0 | 190.42 ± 57.6 |
| C3D1 | 139.60 ± 26.6 | 157.46 ± 53.7 | 329.28 ± 73.5 |
Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve.
| Hours (h) | MSC1936369B 1 mg | MSC1936369B 1.5 mg | MSC1936369B 2.5 mg | MSC1936369B 3.5 mg | MSC1936369B 7 mg | MSC1936369B 14 mg | MSC1936369B 28 mg | MSC1936369B 45 mg | MSC1936369B 68 mg | MSC1936369B 94 mg | MSC1936369B 120 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| C1D1 | 1.500 (1.02 to 1.53) | 0.750 (0.50 to 4.25) | 1.500 (1.00 to 2.50) | 1.500 (1.00 to 2.17) | 1.500 (1.00 to 2.50) | 1.000 (0.50 to 2.00) | 1.500 (1.00 to 4.00) | 1.017 (1.00 to 2.50) | 1.000 (0.98 to 1.50) | 1.483 (0.52 to 2.17) | 1.017 (0.50 to 6.00) |
| C1D12 | 1.633 (0.50 to 2.50) | 0.533 (0.33 to 2.00) | 1.000 (1.00 to 2.50) | 1.000 (1.00 to 1.08) | 1.017 (1.00 to 1.05) | 1.500 (1.50 to 1.50) | 1.000 (0.50 to 3.92) | 2.000 (0.75 to 2.52) | 1.000 (0.50 to 4.00) | 1.500 (1.50 to 2.00) | 1.083 (0.52 to 8.00) |
| C3D1 | 1.52 (1.52 to 1.52) | 0.500 (0.50 to 0.50) | 1.52 (1.52 to 1.52) | 1.000 (0.50 to 2.67) | 1.517 (1.00 to 4.05) | 1.500 (1.50 to 1.50) | 1.000 (1.00 to 3.58) | 1.508 (0.50 to 2.52) | — | 1.767 (1.50 to 2.03) | 2.000 (0.50 to 4.00) |
Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve.
| Hours (h) | MSC1936369B 1 mg | MSC1936369B 2 mg | MSC1936369B 3.5 mg | MSC1936369B 5 mg | MSC1936369B 7 mg | MSC1936369B 14 mg | MSC1936369B 28 mg | MSC1936369B 45 mg | MSC1936369B 68 mg | MSC1936369B 94 mg | MSC1936369B 120 mg | MSC1936369B 150 mg | MSC1936369B 195 mg | MSC1936369B 255 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C1D1 | 1.500 (1.50 to 1.92) | 1.017 (0.50 to 2.50) | 1.500 (1.00 to 2.00) | 1.000 (0.50 to 24.98) | 0.533 (0.52 to 2.00) | 1.500 (0.50 to 4.00) | 1.000 (0.58 to 2.02) | 0.500 (0.50 to 1.02) | 1.000 (0.47 to 1.50) | 1.500 (0.50 to 1.58) | 1.250 (0.33 to 2.02) | 1.500 (0.58 to 4.00) | 1.250 (0.50 to 2.50) | 2.000 (0.50 to 2.50) |
| C1D15 | 1.500 (1.42 to 2.00) | 0.967 (0.52 to 1.50) | 2.000 (0.43 to 2.00) | 0.667 (0.50 to 2.50) | 1.008 (1.00 to 1.02) | 1.500 (1.50 to 4.00) | 1.017 (0.50 to 2.12) | 1.500 (0.67 to 1.52) | 1.250 (1.00 to 1.50) | 1.500 (1.50 to 2.02) | 2.000 (1.00 to 2.08) | 1.517 (1.00 to 7.92) | 1.250 (0.50 to 3.00) | 1.458 (1.00 to 2.00) |
| C3D1 | 1.250 (1.00 to 1.50) | 2.000 (2.00 to 2.00) | 1.258 (1.00 to 1.52) | 1.000 (1.00 to 1.00) | 2.500 (2.50 to 2.50) | — | 1.50 (1.50 to 1.50) | — | 0.500 (0.50 to 0.50) | 2.000 (2.00 to 2.00) | 1.042 (0.58 to 1.50) | 1.333 (1.00 to 2.10) | 1.000 (0.50 to 2.02) | 1.000 (1.00 to 1.67) |
Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve. Summarized data over Day 1 and Day 2 was reported.
| Hours (h) | MSC1936369B 90 mg | MSC1936369B 150 mg |
|---|---|---|
| Fasted | 1.600 (0.33 to 2.50) | 1.000 (1.00 to 1.00) |
| Fed | 2.033 (1.50 to 4.00) | 6.000 (6.00 to 6.00) |
Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve.
| Hours (h) | MSC1936369B 60 mg | MSC1936369B 90 mg |
|---|---|---|
| C1D1 | 1.033 (1.00 to 1.50) | 1.500 (0.50 to 2.03) |
| C1D15 | 2.500 (1.52 to 2.50) | 1.492 (0.50 to 4.00) |
| C3D1 | 2.000 (1.50 to 2.50) | 1.000 (0.57 to 2.10) |
Time to reach the maximum plasma concentration (Tmax) was obtained directly from the concentration versus time curve.
| Hours (h) | MSC1936369B 45 mg | MSC1936369B 60 mg | MSC1936369B 75 mg |
|---|---|---|---|
| C1D1 | 1.500 (1.00 to 2.00) | 1.000 (0.50 to 4.00) | 0.667 (0.47 to 2.50) |
| C1D15 | 1.500 (1.03 to 2.00) | 1.500 (0.50 to 2.55) | 1.500 (0.97 to 4.08) |
| C3D1 | 1.467 (0.92 to 2.02) | 1.183 (0.50 to 2.07) | 1.467 (0.50 to 1.57) |
Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.
| hour*nanogram per milliliter (h*ng/mL) | MSC1936369B 1 mg | MSC1936369B 1.5 mg | MSC1936369B 2.5 mg | MSC1936369B 3.5 mg | MSC1936369B 7 mg | MSC1936369B 14 mg | MSC1936369B 28 mg | MSC1936369B 45 mg | MSC1936369B 68 mg | MSC1936369B 94 mg | MSC1936369B 120 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| C1D1 | 4.6 ± 431.3 | 5.2 ± 63.9 | 18.5 ± 49.8 | 22.7 ± 29.2 | 52.7 ± 74.5 | 213.9 ± 84.0 | 531.3 ± 55.4 | 889.0 ± 31.9 | 1624.8 ± 36.1 | 1748.1 ± 38.8 | 2292.4 ± 52.5 |
| C1D12 | 7.0 ± 269.8 | 6.0 ± 89.3 | 26.0 ± 55.0 | 35.9 ± 79.7 | 83.6 ± 67.7 | 182.0 ± 125.1 | 691.9 ± 51.4 | 880.0 ± 45.7 | 1900.3 ± 99.7 | 1991.4 ± 19.2 | 1682.4 ± 52.4 |
| C3D1 | 6.9 ± NA | 2.7 ± NA | 21.0 ± NA | 23.0 ± 38.2 | 45.2 ± 51.8 | 113.2 ± NA | 334.9 ± 47.8 | 666.3 ± 52.3 | — | 876.7 ± 20.4 | 2064.1 ± 55.0 |
Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.
| hour*ng/mL | MSC1936369B 1 mg | MSC1936369B 2 mg | MSC1936369B 3.5 mg | MSC1936369B 5 mg | MSC1936369B 7 mg | MSC1936369B 14 mg | MSC1936369B 28 mg | MSC1936369B 45 mg | MSC1936369B 68 mg | MSC1936369B 94 mg | MSC1936369B 120 mg | MSC1936369B 150 mg | MSC1936369B 195 mg | MSC1936369B 255 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C1D1 | 1.9 ± 331.6 | 8.2 ± 53.1 | 6.7 ± 292.9 | 67.9 ± 93.9 | 74.4 ± 19.4 | 188.4 ± 61.7 | 625.7 ± 20.6 | 808.0 ± 15.7 | 861.1 ± 112.4 | 1484.6 ± 13.0 | 2287.0 ± 96.6 | 2216.5 ± 75.7 | 3415.6 ± 44.5 | 4041.3 ± 60.8 |
| C1D15 | 4.3 ± 228.5 | 22.2 ± 42.1 | 13.8 ± 66.9 | 79.3 ± 57.9 | 67.8 ± 53.9 | 161.5 ± 14.1 | 621.2 ± 12.7 | 906.3 ± 15.4 | 1553.9 ± 122.5 | 1826.2 ± 17.9 | 1862.3 ± 96.4 | 2086.6 ± 69.9 | 3436.8 ± 64.7 | 5765.9 ± 15.3 |
| C3D1 | 0.5 ± 76.6 | 10.2 ± NA | 26.2 ± 15.6 | 40.5 ± 26.9 | 46.1 ± NA | — | 306.2 ± NA | — | 1394.7 ± 24.6 | 1299.3 ± NA | 2053.6 ± 71.1 | 2171.2 ± 59.4 | 2484.5 ± 53.6 | 4906.3 ± 19.2 |
Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule. Summarized data over Day 1 and Day 2 was reported.
| hour*ng/mL | MSC1936369B 90 mg | MSC1936369B 150 mg |
|---|---|---|
| Fasted | 1509.6 ± 46.6 | 3286 ± NA |
| Fed | 1458.3 ± 41.3 | 5072.9 ± NA |
Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.
| hour*ng/mL | MSC1936369B 60 mg | MSC1936369B 90 mg |
|---|---|---|
| C1D1 | 1229.3 ± 96.5 | 1544.9 ± 57.1 |
| C1D15 | 1532.4 ± 80.4 | 1428.8 ± 63.6 |
| C3D1 | 1392.3 ± 35.2 | 1122.5 ± 45.2 |
Area under the plasma concentration vs time curve from time zero to the last sampling time t at which the concentration was at or above the lower limit of quantification (LLQ). AUC0-t was to be calculated according to the mixed log-linear trapezoidal rule.
| hour*ng/mL | MSC1936369B 45 mg | MSC1936369B 60 mg | MSC1936369B 75 mg |
|---|---|---|---|
| C1D1 | 407.2 ± 40.7 | 681.4 ± 43.7 | 791.1 ± 62.3 |
| C1D15 | 589.3 ± 66.5 | 838.8 ± 43.9 | 710.3 ± 65.0 |
| C3D1 | 450.0 ± 57.1 | 577.0 ± 72.5 | 1005.0 ± 25.6 |
AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.
| hour*ng/mL | MSC1936369B 1 mg | MSC1936369B 1.5 mg | MSC1936369B 2.5 mg | MSC1936369B 3.5 mg | MSC1936369B 7 mg | MSC1936369B 14 mg | MSC1936369B 28 mg | MSC1936369B 45 mg | MSC1936369B 68 mg | MSC1936369B 94 mg | MSC1936369B 120 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| C1D1 | 136.2 ± 9.2 | 6.2 ± NA | 55.5 ± 321.8 | 31.4 ± 29.7 | 61.3 ± 66.9 | 234.1 ± 70.2 | 574.2 ± 50.0 | 924.2 ± 32.7 | 1699.7 ± 36.1 | 1836.4 ± 42.8 | 2773.5 ± 54.7 |
| C1D12 | 38.3 ± 254.8 | 9.4 ± NA | 43.8 ± 58.7 | 47.5 ± 68.1 | 105.6 ± 57.6 | 206.3 ± 106.5 | 805.6 ± 58.9 | 960.7 ± 46.9 | 2108.2 ± 115.0 | 2257.6 ± 30.1 | 2022.8 ± 41.3 |
| C3D1 | 15.4 ± NA | — | 47.6 ± NA | 34.4 ± 37.6 | 55.5 ± 90.0 | 134.5 ± NA | 489.8 ± 55.2 | 1072.1 ± 121.6 | — | 1056.0 ± 26.6 | 3477.6 ± 102.0 |
AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration was at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.
| hour*ng/mL | MSC1936369B 1 mg | MSC1936369B 2 mg | MSC1936369B 3.5 mg | MSC1936369B 5 mg | MSC1936369B 7 mg | MSC1936369B 14 mg | MSC1936369B 28 mg | MSC1936369B 45 mg | MSC1936369B 68 mg | MSC1936369B 94 mg | MSC1936369B 120 mg | MSC1936369B 150 mg | MSC1936369B 195 mg | MSC1936369B 255 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C1D1 | — | 23.4 ± 65.7 | 23.6 ± 22.5 | 59.1 ± 6.2 | 90.3 ± 30.8 | 218.4 ± 62.1 | 646.9 ± 20.7 | 820.4 ± 15.7 | 885.8 ± 111.0 | 1525.6 ± 13.2 | 2424.2 ± 109.7 | 2287.8 ± 77.4 | 3602.2 ± 46.2 | 4300.3 ± 54.2 |
| C1D15 | 15.7 ± 10.6 | 33.3 ± 45.8 | 21.9 ± 91.5 | 102.0 ± 63.6 | 89.7 ± 85.9 | 172.2 ± 9.0 | 669.1 ± 10.5 | 933.9 ± 15.4 | 1665.2 ± 132.1 | 1893.2 ± 17.5 | 2129.0 ± 123.7 | 2029.9 ± 63.3 | 3900.8 ± 64.3 | 6232.1 ± 7.0 |
| C3D1 | — | 15.4 ± NA | 41.2 ± 41.4 | 49.5 ± 17.4 | 58.1 ± NA | — | 415.6 ± NA | — | 1655.1 ± 19.1 | 1584.8 ± NA | 2461.3 ± 64.3 | 2796.2 ± 59.3 | 3452.9 ± 61.6 | 5651.1 ± 23.5 |
AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase. Summarized data over Day 1 and Day 2 was reported.
| hour*ng/mL | MSC1936369B 90 mg | MSC1936369B 150 mg |
|---|---|---|
| Fasted | 1580.6 ± 48.7 | 3344.3 ± NA |
| Fed | 1495.7 ± 41.8 | 5633.8 ± NA |
AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.
| hour*ng/mL | MSC1936369B 45 mg | MSC1936369B 60 mg | MSC1936369B 75 mg |
|---|---|---|---|
| C1D1 | 527.6 ± 57.4 | 742.3 ± 47.1 | 939.9 ± 67.3 |
| C1D15 | 674.1 ± 73.6 | 1004.2 ± 46.4 | 978.4 ± 63.7 |
| C3D1 | 696.0 ± 101.4 | 700.8 ± 79.0 | 1285.7 ± 29.0 |
AUC0-inf was calculated by combining AUC0-t and AUCextra. AUC extra represents an extrapolated value obtained by Clast/ λz, where Clast is the calculated plasma concentration at the last sampling time point at which the measured plasma concentration is at or above the Lower Limit of quantification (LLQ) and λz is the apparent terminal rate constant determined by log-linear regression analysis of the measured plasma concentrations of the terminal log-linear phase.
| hour*ng/mL | MSC1936369B 60 mg | MSC1936369B 90 mg |
|---|---|---|
| C1D1 | 1253.1 ± 96.9 | 1581.4 ± 56.6 |
| C1D15 | 1753.9 ± 93.1 | 1517.1 ± 65.6 |
| C3D1 | 1597.0 ± 50.7 | 1400.3 ± 53.0 |
Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz. As AUCextra was \>20% of AUC0-inf, t1/2 derived from λz was regarded as implausible \& not calculated for arms MSC1936369B 1mg, 1.5mg, 2.5 mg.
| Hours (h) | MSC1936369B 1 mg | MSC1936369B 1.5 mg | MSC1936369B 2.5 mg | MSC1936369B 3.5 mg | MSC1936369B 7 mg | MSC1936369B 14 mg | MSC1936369B 28 mg | MSC1936369B 45 mg | MSC1936369B 68 mg | MSC1936369B 94 mg | MSC1936369B 120 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| C1D1 | — | — | — | 3.346 ± NA | 3.405 ± 52.1 | 4.599 ± 29.1 | 4.781 ± 39.4 | 5.389 ± 9.4 | 5.335 ± 23.6 | 5.351 ± 15.9 | 5.247 ± 17.1 |
| C1D12 | — | — | — | 4.985 ± 123.5 | 9.249 ± NA | 3.236 ± 19.4 | 6.750 ± 21.5 | 4.688 ± 60.4 | 6.926 ± 33.6 | 5.672 ± 15.4 | 3.964 ± 44.7 |
| C3D1 | — | — | — | — | 2.959 ± NA | 2.811 ± NA | — | 2.931 ± NA | — | 2.842 ± NA | 3.038 ± 3.4 |
Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz. As AUCextra was \>20% of AUC0-inf, t1/2 derived from λz was regarded as implausible \& not calculated for arms MSC1936369B 1mg, 2mg, 3.5 mg.
| Hours (h) | MSC1936369B 1 mg | MSC1936369B 2 mg | MSC1936369B 3.5 mg | MSC1936369B 5 mg | MSC1936369B 7 mg | MSC1936369B 14 mg | MSC1936369B 28 mg | MSC1936369B 45 mg | MSC1936369B 68 mg | MSC1936369B 94 mg | MSC1936369B 120 mg | MSC1936369B 150 mg | MSC1936369B 195 mg | MSC1936369B 255 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C1D1 | — | — | — | — | 2.594 ± 5.0 | 5.119 ± 30.5 | 5.115 ± 6.6 | 4.187 ± 10.3 | 3.305 ± 84.0 | 4.826 ± 14.0 | 5.057 ± 45.3 | 4.904 ± 18.8 | 5.641 ± 21.6 | 4.313 ± 29.6 |
| C1D15 | — | — | — | 2.941 ± NA | 2.335 ± NA | 4.443 ± 67.3 | 6.646 ± 19.5 | 5.277 ± 8.0 | 6.441 ± 28.4 | 5.193 ± 11.1 | 4.851 ± 7.9 | 5.479 ± 14.1 | 6.016 ± 18.9 | 4.847 ± 16.4 |
| C3D1 | — | — | — | 2.732 ± NA | — | — | — | — | 3.477 ± 11.0 | 2.853 ± NA | 2.863 ± 22.0 | 2.418 ± 25.2 | 2.628 ± 9.4 | 2.260 ± 34.4 |
Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz. Summarized data over Day 1 and Day 2 was reported.
| Hour (h) | MSC1936369B 90 mg | MSC1936369B 150 mg |
|---|---|---|
| Fasted | 4.898 ± 36.7 | 4.452 ± NA |
| Fed | 4.534 ± 18.3 | 6.123 ± NA |
Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz.
| Hour (h) | MSC1936369B 60 mg | MSC1936369B 90 mg |
|---|---|---|
| C1D1 | 4.236 ± 1.3 | 4.097 ± 33.5 |
| C1D15 | 5.259 ± 14.8 | 5.599 ± 30.1 |
| C3D1 | 1.780 ± NA | 2.680 ± 21.1 |
Terminal half-life is the time measured for the concentration to decrease by one half. Terminal half-life calculated by natural log 2 divided by λz.
| Hour (h) | MSC1936369B 45 mg | MSC1936369B 60 mg | MSC1936369B 75 mg |
|---|---|---|---|
| C1D1 | 2.050 ± NA | 2.509 ± 25.1 | 2.814 ± 20.2 |
| C1D15 | 2.890 ± 23.8 | 3.265 ± 18.6 | 3.210 ± 23.8 |
| C3D1 | 3.144 ± NA | 2.636 ± 17.0 | 3.260 ± 10.6 |
Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from plasma, CL= Dose/AUC0-inf. As AUCextra was \>20% of AUC0-inf, CL/f derived from λz was regarded as implausible \& not calculated for arms MSC1936369B 1mg, 1.5mg, 2.5 mg.
| Liter per hour | MSC1936369B 1 mg | MSC1936369B 1.5 mg | MSC1936369B 2.5 mg | MSC1936369B 3.5 mg | MSC1936369B 7 mg | MSC1936369B 14 mg | MSC1936369B 28 mg | MSC1936369B 45 mg | MSC1936369B 68 mg | MSC1936369B 94 mg | MSC1936369B 120 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| C1D1 | — | — | — | 132.69 ± NA | 114.26 ± 66.9 | 59.80 ± 70.2 | 48.76 ± 50.0 | 48.69 ± 32.7 | 40.01 ± 36.1 | 50.45 ± 41.2 | 47.82 ± 53.3 |
| C1D12 | — | — | — | 70.60 ± 77.3 | 44.55 ± NA | 62.53 ± 92.6 | 37.49 ± 55.2 | 49.37 ± 43.8 | 35.80 ± 99.7 | 50.88 ± 19.6 | 61.44 ± 42.3 |
| C3D1 | — | — | — | — | 217.56 ± NA | 104.07 ± NA | — | 82.35 ± NA | — | 107.06 ± NA | 72.25 ± 35.7 |
Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from plasma, CL= Dose/AUC0-inf. As AUCextra was \>20% of AUC0-inf, CL/f derived from λz was regarded as implausible \& not calculated for arms MSC1936369B 1mg, 2mg, 3.5 mg.
| Liter per hour | MSC1936369B 1 mg | MSC1936369B 2 mg | MSC1936369B 3.5 mg | MSC1936369B 5 mg | MSC1936369B 7 mg | MSC1936369B 14 mg | MSC1936369B 28 mg | MSC1936369B 45 mg | MSC1936369B 68 mg | MSC1936369B 94 mg | MSC1936369B 120 mg | MSC1936369B 150 mg | MSC1936369B 195 mg | MSC1936369B 255 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C1D1 | — | — | — | — | 90.76 ± 18.3 | 64.09 ± 62.1 | 43.28 ± 20.7 | 54.85 ± 15.7 | 76.77 ± 111.0 | 61.61 ± 13.2 | 49.50 ± 109.7 | 65.57 ± 77.4 | 54.13 ± 46.2 | 60.63 ± 53.4 |
| C1D15 | — | — | — | 59.55 ± NA | 134.9 ± NA | 86.72 ± 12.5 | 45.10 ± 12.7 | 49.65 ± 15.4 | 43.76 ± 122.4 | 51.47 ± 17.9 | 92.42 ± 84.1 | 81.22 ± 65.4 | 53.49 ± 64.3 | 42.20 ± 5.9 |
| C3D1 | — | — | — | 89.34 ± NA | — | — | — | — | 41.08 ± 19.1 | 59.31 ± NA | 48.76 ± 64.3 | 61.04 ± 53.0 | 72.33 ± 63.8 | 44.23 ± 37.5 |
Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from plasma, CL= Dose/AUC0-inf. Summarized data over Day 1 and Day 2 was reported.
| Liter per hour | MSC1936369B 90 mg | MSC1936369B 150 mg |
|---|---|---|
| Fasted | 56.94 ± 48.7 | 44.85 ± NA |
| Fed | 60.17 ± 41.8 | 26.62 ± NA |
Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from plasma, CL= Dose/AUC0-inf.
| Liter per hour | MSC1936369B 60 mg | MSC1936369B 90 mg |
|---|---|---|
| C1D1 | 47.88 ± 96.9 | 56.91 ± 56.6 |
| C1D15 | 48.31 ± 103.9 | 62.85 ± 63.6 |
| C3D1 | 53.36 ± NA | 75.63 ± 59.6 |
Clearance of a drug was a measure of the rate at which a drug is metabolized or eliminated by normal biological processes. Apparent body clearance of the drug from plasma, CL= Dose/AUC0-inf.
| Liter per hour | MSC1936369B 45 mg | MSC1936369B 60 mg | MSC1936369B 75 mg |
|---|---|---|---|
| C1D1 | 114.82 ± NA | 80.83 ± 47.1 | 83.86 ± 67.2 |
| C1D15 | 71.44 ± 69.3 | 66.89 ± 52.1 | 94.48 ± 71.2 |
| C3D1 | 126.1 ± NA | 103.3 ± 66.9 | 77.09 ± 21.0 |
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz. As AUCextra was \>20% of AUC0-inf, Vz/F derived from λz was regarded as implausible \& not calculated for arms MSC1936369B 1mg, 1.5mg, 2.5 mg.
| Liter | MSC1936369B 1 mg | MSC1936369B 1.5 mg | MSC1936369B 2.5 mg | MSC1936369B 3.5 mg | MSC1936369B 7 mg | MSC1936369B 14 mg | MSC1936369B 28 mg | MSC1936369B 45 mg | MSC1936369B 68 mg | MSC1936369B 94 mg | MSC1936369B 120 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| C1D1 | — | — | — | 640.60 ± NA | 561.27 ± 12.9 | 396.76 ± 86.7 | 336.32 ± 78.8 | 378.56 ± 23.0 | 307.90 ± 43.1 | 389.49 ± 28.6 | 361.99 ± 43.0 |
| C1D12 | — | — | — | 507.8 ± 28.3 | 594.5 ± NA | 291.9 ± 73.0 | 365.1 ± 35.0 | 333.9 ± 65.1 | 357.8 ± 53.7 | 416.3 ± 35.8 | 351.4 ± 37.5 |
| C3D1 | — | — | — | — | 928.91 ± NA | 422.04 ± NA | — | 348.19 ± NA | — | 438.91 ± NA | 316.63 ± 33.9 |
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz. As AUCextra was \>20% of AUC0-inf, Vz/F derived from λz was regarded as implausible \& not calculated for arms MSC1936369B 1mg, 2mg, 3.5 mg.
| Liter | MSC1936369B 1 mg | MSC1936369B 2 mg | MSC1936369B 3.5 mg | MSC1936369B 5 mg | MSC1936369B 7 mg | MSC1936369B 14 mg | MSC1936369B 28 mg | MSC1936369B 45 mg | MSC1936369B 68 mg | MSC1936369B 94 mg | MSC1936369B 120 mg | MSC1936369B 150 mg | MSC1936369B 195 mg | MSC1936369B 255 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C1D1 | — | — | — | — | 339.58 ± 13.2 | 473.32 ± 81.2 | 319.40 ± 27.0 | 331.36 ± 13.3 | 366.00 ± 22.8 | 428.99 ± 22.7 | 361.12 ± 58.1 | 463.92 ± 68.7 | 440.55 ± 41.7 | 377.28 ± 42.4 |
| C1D15 | — | — | — | 252.7 ± NA | 454.6 ± NA | 555.9 ± 84.7 | 432.5 ± 30.7 | 378.0 ± 23.6 | 406.6 ± 76.5 | 385.6 ± 25.9 | 646.9 ± 96.3 | 642.1 ± 63.5 | 464.2 ± 64.9 | 295.1 ± 13.4 |
| C3D1 | — | — | — | 352.10 ± NA | — | — | — | — | 206.07 ± 30.5 | 244.16 ± NA | 201.39 ± 95.6 | 212.92 ± 34.4 | 274.24 ± 53.8 | 144.24 ± 79.1 |
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz. Summarized data over Day 1 and Day 2 was reported.
| Liter | MSC1936369B 90 mg | MSC1936369B 150 mg |
|---|---|---|
| Fasted | 402.4 ± 49.0 | 288.1 ± NA |
| Fed | 393.6 ± 40.5 | 235.2 ± NA |
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz
| Liter | MSC1936369B 60 mg | MSC1936369B 90 mg |
|---|---|---|
| C1D1 | 292.61 ± 99.0 | 336.38 ± 47.1 |
| C1D15 | 366.5 ± 131.6 | 507.7 ± 66.0 |
| C3D1 | 137.0 ± NA | 292.5 ± 47.3 |
Volume of distribution was defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired plasma concentration of a drug. Apparent volume of distribution during the terminal phase, calculated as Vz = Dose/AUC0-inf multiplied by λz
| Liter | MSC1936369B 45 mg | MSC1936369B 60 mg | MSC1936369B 75 mg |
|---|---|---|---|
| C1D1 | 339.51 ± NA | 292.59 ± 42.3 | 340.43 ± 57.7 |
| C1D15 | 297.9 ± 57.8 | 315.0 ± 59.4 | 437.6 ± 59.1 |
| C3D1 | 571.8 ± NA | 392.9 ± 81.9 | 362.6 ± 10.2 |
AUCextra was defined as a percentage of AUC0-inf obtained by extrapolation: %AUCextra = (1- \[AUC0-t / AUC0-inf\])\*100. %AUCextra was reported in terms of percentage of AUC0-inf.
| Percentage of AUC 0-∞ | MSC1936369B 1 mg | MSC1936369B 1.5 mg | MSC1936369B 2.5 mg | MSC1936369B 3.5 mg | MSC1936369B 7 mg | MSC1936369B 14 mg | MSC1936369B 28 mg | MSC1936369B 45 mg | MSC1936369B 68 mg | MSC1936369B 94 mg | MSC1936369B 120 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|
| C1D1 | 81.33 ± 21.2 | 42.23 ± NA | 43.45 ± 79.8 | 26.80 ± 27.3 | 13.08 ± 47.7 | 5.31 ± 174.3 | 5.39 ± 112.5 | 3.52 ± 52.0 | 4.08 ± 47.3 | 4.09 ± 75.2 | 5.28 ± 155.8 |
| C1D12 | 50.60 ± 8.6 | 33.84 ± NA | 40.60 ± 5.6 | 21.27 ± 56.8 | 19.82 ± 37.6 | 7.83 ± 193.6 | 6.57 ± 45.0 | 8.17 ± 29.1 | 6.56 ± 185.5 | 7.94 ± 131.8 | 2.97 ± 137.2 |
| C3D1 | 55.15 ± NA | — | 55.79 ± NA | 32.85 ± 14.3 | 21.27 ± 33.1 | 15.84 ± NA | 28.06 ± 30.6 | 27.67 ± 126.0 | — | 16.54 ± 30.2 | 26.05 ± 98.7 |
AUCextra was defined as a percentage of AUC0-inf obtained by extrapolation: %AUCextra = (1- \[AUC0-t / AUC0-inf\])\*100. %AUCextra was reported in terms of percentage of AUC0-inf.
| Percentage of AUC 0-∞ | MSC1936369B 1 mg | MSC1936369B 2 mg | MSC1936369B 3.5 mg | MSC1936369B 5 mg | MSC1936369B 7 mg | MSC1936369B 14 mg | MSC1936369B 28 mg | MSC1936369B 45 mg | MSC1936369B 68 mg | MSC1936369B 94 mg | MSC1936369B 120 mg | MSC1936369B 150 mg | MSC1936369B 195 mg | MSC1936369B 255 mg |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| C1D1 | — | 55.78 ± 11.0 | 31.63 ± 31.2 | 27.25 ± 15.2 | 15.10 ± 63.9 | 12.17 ± 59.8 | 3.29 ± 3.7 | 1.46 ± 30.8 | 2.66 ± 40.8 | 2.60 ± 33.4 | 2.94 ± 181.0 | 2.64 ± 68.3 | 4.36 ± 76.2 | 3.57 ± 149.3 |
| C1D15 | 40.86 ± 2.9 | 33.34 ± 6.4 | 35.29 ± 30.0 | 21.93 ± 20.2 | 19.45 ± 107.4 | 12.45 ± 58.0 | 6.89 ± 32.9 | 2.96 ± 1.9 | 5.00 ± 141.4 | 3.40 ± 33.9 | 5.82 ± 251.8 | 4.82 ± 82.9 | 5.77 ± 72.8 | 5.22 ± 112.2 |
| C3D1 | — | 33.93 ± NA | 33.77 ± 47.7 | 17.27 ± 45.0 | 20.68 ± NA | — | 26.32 ± NA | — | 15.35 ± 29.7 | 18.02 ± NA | 16.22 ± 26.9 | 17.54 ± 83.4 | 23.45 ± 59.4 | 11.15 ± 77.4 |
AUCextra was defined as a percentage of AUC0-inf obtained by extrapolation: AUCextra = (1- \[AUC0-t / AUC0-inf\])\*100. AUCextra was reported in terms of percentage of AUC0-inf. Summarized data over Day 1 and Day 2 was reported.
| Percentage of AUC 0-∞ | MSC1936369B 90 mg | MSC1936369B 150 mg |
|---|---|---|
| Fasted | 2.54 ± 149.8 | 1.74 ± NA |
| Fed | 2.21 ± 56.3 | 9.96 ± NA |
AUCextra was defined as a percentage of AUC0-inf obtained by extrapolation: AUCextra = (1- \[AUC0-t / AUC0-inf\])\*100. AUCextra was reported in terms of percentage of AUC0-inf.
| percentage of AUC 0-∞ | MSC1936369B 60 mg | MSC1936369B 90 mg |
|---|---|---|
| C1D1 | 1.88 ± 16.2 | 2.11 ± 50.0 |
| C1D15 | 7.95 ± 149.3 | 4.28 ± 85.0 |
| C3D1 | 9.11 ± 171.3 | 17.56 ± 50.9 |
AUCextra was defined as a percentage of AUC0-inf obtained by extrapolation: AUCextra = (1- \[AUC0-t / AUC0-inf\])\*100. AUCextra was reported in terms of percentage of AUC0-inf.
| Percentage of AUC 0-∞ | MSC1936369B 45 mg | MSC1936369B 60 mg | MSC1936369B 75 mg |
|---|---|---|---|
| C1D1 | 16.82 ± 128.4 | 7.70 ± 58.3 | 10.90 ± 68.3 |
| C1D15 | 11.78 ± 42.8 | 14.14 ± 51.4 | 19.19 ± 79.3 |
| C3D1 | 30.63 ± 70.7 | 16.43 ± 37.5 | 21.34 ± 21.8 |
| fold change | MSC1936369B Regimen 1 | MSC1936369B Regimen 2 (Without Food Effect + With Food Effect) | MSC1936369B Regimen 3 Once Daily | MSC1936369B Regimen 3 Twice Daily |
|---|---|---|---|---|
| C1D1, Pre-dose (pERK) | 4.524 ± 1.839 | 3.937 ± 1.662 | 4.121 ± 1.743 | 3.629 ± 1.491 |
| C1D1, 2 h post-dose (pERK) | 1.235 ± 0.295 | 1.305 ± 0.755 | 1.178 ± 0.194 | 1.249 ± 0.219 |
| C1D1, 4 h post-dose (pERK) | 3.828 ± 1.715 | 3.422 ± 1.902 | — | — |
| C1D1, 8 h post-dose (pERK) | 1.454 ± 0.515 | 1.454 ± 0.403 | 1.878 ± 0.836 | 1.821 ± 0.514 |
| C1D2, Pre-dose (pERK) | 2.853 ± 1.399 | 2.411 ± 1.031 | 3.081 ± 1.249 | 2.069 ± 0.748 |
| C1D5, Pre-dose (pERK) | 2.722 ± 1.326 | — | — | — |
| C1D8, Pre-dose (pERK) | 4.48 ± 2.119 | 2.868 ± 1.473 | 2.541 ± 1.338 | 2.235 ± 0.739 |
| C1D12-15, Pre-dose (pERK) | 3.257 ± 1.671 | 3.265 ± 1.845 | 3.241 ± 2.249 | 2.16 ± 0.814 |
| C1D12-15, 2 h Post-dose (pERK) | 1.252 ± 0.217 | 1.293 ± 0.447 | 1.471 ± 0.529 | 1.315 ± 0.218 |
| C1D12-15, 8 h Post-dose (pERK) | 1.514 ± 0.391 | 1.653 ± 0.571 | 1.902 ± 0.87 | 1.98 ± 0.827 |
| C1D12-15, 24 h Post-dose (pERK) | 2.768 ± 1.594 | 2.476 ± 0.958 | 2.598 ± 1.185 | 2.043 ± 0.76 |
| C3D1, Pre-dose (pERK) | 5.179 ± 2.151 | 3.716 ± 1.875 | — | — |
| C3D1, 2 h Post-dose (pERK) | 1.795 ± 0.687 | 1.288 ± 0.327 | — | — |
| C3D1, 4 h Post-dose (pERK) | 3.106 ± 0.461 | 2.688 ± 2.065 | — | — |
| C1D1, Pre-dose (Tot ERK) | 1.1 ± 0.468 | 1.075 ± 0.25 | 1.02 ± 0.169 | 1.086 ± 0.277 |
| C1D1, 2 h post-dose (Tot ERK) | 1.063 ± 0.215 | 1.069 ± 0.247 | 1.078 ± 0.151 | 1.079 ± 0.193 |
| C1D1, 4 h post-dose (Tot ERK) | 1.059 ± 0.621 | 1.012 ± 0.286 | — | — |
| C1D1, 8 h post-dose (Tot ERK) | 1.058 ± 0.16 | 1.095 ± 0.31 | 1.078 ± 0.143 | 1.098 ± 0.161 |
| C1D2, Pre-dose (Tot ERK) | 1.075 ± 0.103 | 1.13 ± 0.455 | 1.013 ± 0.273 | 1.108 ± 0.154 |
| C1D5, Pre-dose (Tot ERK) | 1.163 ± 0.146 | — | — | — |
| C1D8, Pre-dose (Tot ERK) | 1.233 ± 0.674 | 1.108 ± 0.353 | 0.944 ± 0.117 | 1.049 ± 0.133 |
| C1D12-15, Pre-dose (Tot ERK) | 1.223 ± 0.476 | 1.118 ± 0.268 | 1.333 ± 0.878 | 1.047 ± 0.144 |
| C1D12-15, 2 h Post-dose (Tot ERK) | 1.04 ± 0.102 | 1.125 ± 0.34 | 1.335 ± 0.754 | 1.059 ± 0.14 |
| C1D12-15, 8 h Post-dose (Tot ERK) | 0.994 ± 0.165 | 1.041 ± 0.237 | 1.044 ± 0.238 | 1.026 ± 0.146 |
| C1D12-15, 24 h Post-dose (Tot ERK) | 1.047 ± 0.153 | 1.045 ± 0.183 | 1.048 ± 0.139 | 1.068 ± 0.141 |
| C3D1, Pre-dose (Tot ERK) | 1.074 ± 0.34 | 1.138 ± 0.306 | — | — |
| C3D1, 2 h Post-dose (Tot ERK) | 1.087 ± 0.413 | 1.251 ± 0.29 | — | — |
| C3D1, 4 h Post-dose (Tot ERK) | 0.674 ± 0.304 | 1.052 ± 0.182 | — | — |
Number of subjects with clinical benefit (CR, PR, or SD) and PD according to Response Evaluation Criteria in Solid Tumors (RECIST Version 1.0) was reported. CR: defined as disappearance of all target and all non-target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR: defined as at least a 30% decrease in sum of longest diameter of target lesions, taking as reference the baseline sum of longest diameter. PD:defined as at least a 20% increase in sum of longest diameter of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study) or unequivocal progression of existing non-target lesions. SD: defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum of longest diameter while on study.
| Subjects | MSC1936369B Regimen 1 | MSC1936369B Regimen 2 and Regimen 2 Food Effect | MSC1936369B Regimen 3 Once Daily (QD) | MSC1936369B Regimen 3 Twice Daily |
|---|---|---|---|---|
| CR | 0 | 0 | 0 | 1 |
| PR | 0 | 4 | 2 | 6 |
| SD | 19 | 34 | 9 | 14 |
| PD | 20 | 33 | 4 | 12 |
Collected over Baseline up to 253 weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| MSC1936369B Regimen 1 | — | 23/49 (46.9%) | 47/49 (95.9%) |
| MSC1936369B Regimen 2 (Without Food Effect + With Food Effect) | — | 45/82 (54.9%) | 80/82 (97.6%) |
| MSC1936369B Regimen 3 Once Daily (QD) | — | 8/15 (53.3%) | 15/15 (100%) |
| MSC1936369B Regimen 3 Twice Daily | — | 21/34 (61.8%) | 34/34 (100%) |
| Event | MSC1936369B Regimen 1 | MSC1936369B Regimen 2 (Without Food Effect + With Food Effect) | MSC1936369B Regimen 3 Once Daily (QD) | MSC1936369B Regimen 3 Twice Daily |
|---|---|---|---|---|
| General physical health deteriorationGeneral disorders | 7/49 | 13/82 | 2/15 | 2/34 |
| DiarrhoeaGastrointestinal disorders | 0/49 | 2/82 | 2/15 | 4/34 |
| NauseaGastrointestinal disorders | 0/49 | 0/82 | 2/15 | 1/34 |
| HeadacheNervous system disorders | 0/49 | 1/82 | 2/15 | 1/34 |
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 0/49 | 2/82 | 0/15 | 3/34 |
| PyrexiaGeneral disorders | 2/49 | 3/82 | 1/15 | 2/34 |
| Vision blurredEye disorders | 0/49 | 0/82 | 1/15 | 0/34 |
| Pulmonary embolismRespiratory, thoracic and mediastinal disorders | 0/49 | 4/82 | 1/15 | 0/34 |
| ThrombophlebitisVascular disorders | 1/49 | 0/82 | 1/15 | 0/34 |
| DehydrationMetabolism and nutrition disorders | 0/49 | 1/82 | 1/15 | 0/34 |
| Event | MSC1936369B Regimen 1 | MSC1936369B Regimen 2 (Without Food Effect + With Food Effect) | MSC1936369B Regimen 3 Once Daily (QD) | MSC1936369B Regimen 3 Twice Daily |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 25/49 | 46/82 | 14/15 | 29/34 |
| Oedema peripheralGeneral disorders | 12/49 | 30/82 | 9/15 | 21/34 |
| Macular detachmentEye disorders | 3/49 | 14/82 | 9/15 | 16/34 |
| AstheniaGeneral disorders | 27/49 | 38/82 | 8/15 | 12/34 |
| Dermatitis acneiformSkin and subcutaneous tissue disorders | 7/49 | 19/82 | 7/15 | 12/34 |
| NauseaGastrointestinal disorders | 21/49 | 26/82 | 6/15 | 15/34 |
| RashSkin and subcutaneous tissue disorders | 9/49 | 18/82 | 6/15 | 14/34 |
| PruritusSkin and subcutaneous tissue disorders | 6/49 | 13/82 | 6/15 | 6/34 |
| PyrexiaGeneral disorders | 9/49 | 13/82 | 3/15 | 12/34 |
| VomitingGastrointestinal disorders | 15/49 | 28/82 | 2/15 | 11/34 |
Safety analysis set included all subjects who received at least 1 dose of MSC1936369B treatment.
| Age, Customized(Participants) | MSC1936369B Regimen 1 | MSC1936369B Regimen 2 (Without Food Effect + With Food Effect) | MSC1936369B Regimen 3 Once Daily (QD) | MSC1936369B Regimen 3 Twice Daily | Total |
|---|---|---|---|---|---|
| >= 18 - <45 Years | 4 | 10 | 4 | 7 | 25 |
| >=45 - <65 Years | 30 | 49 | 9 | 13 | 101 |
| >=65 Years | 15 | 23 | 2 | 14 | 54 |
| Sex: Female, Male(Participants) | MSC1936369B Regimen 1 | MSC1936369B Regimen 2 (Without Food Effect + With Food Effect) | MSC1936369B Regimen 3 Once Daily (QD) | MSC1936369B Regimen 3 Twice Daily | Total |
|---|---|---|---|---|---|
| Female | 20 | 30 | 9 | 11 | 70 |
| Male | 29 | 52 | 6 | 23 | 110 |
Ran from Dec 2007 to primary completion in Mar 2013, 63 months.
Results were first posted in Oct 2018, 5 years 6 months after primary completion.
Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's 63 months is above that.
Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Feb 2018. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Merck KGaA, Darmstadt, Germany →